There is no set time limit for Stelara (ustekinumab). Most people who respond well to it stay on it indefinitely, often for years or even decades, because the conditions it treats (psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis) are chronic and tend to return when treatment stops. The real question isn’t how long you’re allowed to stay on it, but how long it keeps working for you.
Stelara Is Designed as Long-Term Therapy
Stelara is a maintenance medication, not a short-course treatment. Once you reach a stable dose schedule (typically every 8 or 12 weeks, depending on your condition), the expectation is that you’ll continue as long as the drug remains effective and you tolerate it well. No prescribing guidelines set a maximum duration. Clinical trials and extension studies have tracked patients on continuous treatment for five years and beyond, and many people in real-world practice have been on it even longer.
A large pooled safety analysis covering Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis followed over 6,700 patients on Stelara for up to five years. Serious infections like pneumonia and cellulitis were actually reported at lower rates in the Stelara group than in the placebo group. Rates of cancer and death were low across the board. This safety profile is one of the reasons doctors are comfortable keeping patients on it long term.
How Well It Works Over Time
For ulcerative colitis, the UNIFI long-term extension study confirmed that Stelara maintained steroid-free remission and endoscopic improvement through four years of continuous treatment. At the four-year mark (week 200), about 55% of patients were still in symptomatic remission, and among those, over 96% had achieved that without needing steroids. Roughly 80% of patients who underwent endoscopic evaluation showed improvement in their intestinal lining.
That said, Stelara doesn’t work forever for everyone. Some people lose their response over time. In inflammatory bowel disease, the annual rate of losing response runs around 20% per patient-year. That means each year you’re on it, there’s roughly a one-in-five chance it stops controlling your symptoms as well as it did. This is a common phenomenon with biologic medications, not something unique to Stelara.
Why Some People Lose Response
Your immune system can sometimes develop antibodies against a biologic drug, treating it like a foreign invader and clearing it from your body faster. With Stelara, this happens less frequently than with some older biologics. Research published in 2023 found that anti-drug antibody formation against Stelara was not strongly associated with reduced effectiveness or lower drug levels in the blood. When antibodies do form, they can speed up how quickly your body breaks down the drug, which may gradually reduce its effectiveness.
Loss of response can also happen for reasons unrelated to antibodies. Disease progression, changes in the underlying inflammatory pathway, or new complications can all play a role.
What Happens if It Stops Working
If Stelara starts losing its effect, doctors typically try shortening the interval between doses before switching to a different medication. In one study of 163 Crohn’s disease patients, about a third needed dose intensification, most commonly moving from every 8 weeks to every 4 weeks. Of those who had their dose intensified, nearly 63% were still on Stelara more than a year later. So for many people, adjusting the schedule can buy significant additional time on a drug that’s otherwise working well.
If dose adjustment doesn’t recapture response, switching to a different class of biologic is the usual next step.
What Happens if You Stop While in Remission
Some people wonder whether they can stop Stelara once they feel well. The short answer: relapse rates are high. A multicenter study tracking patients who discontinued biologic therapy while in remission found that 80% of those who stopped non-anti-TNF biologics (a category that includes Stelara) relapsed, with a median time to relapse of about 11 months. That’s a worse relapse rate and shorter time to flare compared to patients stopping older anti-TNF biologics.
This is the core reason most gastroenterologists and dermatologists recommend staying on Stelara even when you feel great. Remission usually depends on continued treatment. Feeling well doesn’t mean the underlying disease is gone; it means the medication is doing its job.
Cost and Access for Long-Term Use
One practical barrier to staying on Stelara long term has been cost. As a brand-name biologic, it carries a high price tag. Biosimilar versions are now entering the market, which should improve affordability over time. Celltrion’s biosimilar (Steqeyma) became available in some markets in 2025, and additional biosimilars from Sandoz and Samsung Bioepis are in various stages of regulatory review. These biosimilars contain the same active ingredient and are held to the same efficacy and safety standards. If you’ve been stable on Stelara, transitioning to a biosimilar is generally straightforward and shouldn’t change your treatment experience in a meaningful way.
For most people who respond to Stelara, the realistic plan is to stay on it for as long as it keeps working, potentially for many years. The drug’s relatively favorable safety profile, low rate of antibody development, and the option to intensify dosing if response fades all support long-term use. Stopping voluntarily while in remission carries a high likelihood of relapse within about a year.